bgb-43395
Small moleculeexperimental
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2023 (NCT06120283)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Cyclin-dependent kinase 4INHIBITOR
CDK4 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07226349 | Phase 1 | Dec 2, 2025 | BeOne Medicines |
| NCT06756932 | Phase 1 | Feb 4, 2025 | BeOne Medicines |
| NCT06761898 | Phase 1 | Jan 14, 2025 | BeOne Medicines |
| NCT06253195 | Phase 1 | Apr 1, 2024 | BeOne Medicines |
| NCT06120283 | Phase 1 | Dec 1, 2023 | BeOne Medicines |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| BeOne Medicines | For profit | 5 | 5 | 1 | 2023 |
1 organizations
Page 1 / 1